Form 4: Astria Therapeutics Director Michael Kishbauch Granted Stock Options

Astria Therapeutics, Inc. Director Michael D. Kishbauch has been granted 26,550 stock options with an exercise price of $5.79, vesting over one year.

Summary

• Michael D. Kishbauch, a Director of Astria Therapeutics, Inc. (ATXS), was granted 26,550 stock options.
• The options have an exercise price of $5.79 per share.
• The grant date for these options was June 11, 2025.
• The options will vest in their entirety on the one-year anniversary of the grant date, specifically June 11, 2026, contingent on Mr. Kishbauch's continued service as a director.
• The options are exercisable from the vesting date until their expiration on June 10, 2035.

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (stock option grant) for a director, which is generally viewed as neutral to slightly positive as it aligns management interests with shareholders. There are no negative or highly positive surprises.

Positives

• The grant of stock options to Director Michael D. Kishbauch aligns his interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• This form of compensation is a standard practice to attract and retain experienced board members.

Future Outlook

The stock options granted to Director Michael D. Kishbauch are set to vest in their entirety on June 11, 2026, contingent upon his continued service, providing a future incentive for his engagement with the company.

Management Comments

• "This option was granted on June 11, 2025 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages. This aligns the interests of directors with long-term shareholder value creation, a critical aspect in an industry characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly within the biotech sector.
• While the specific number of options and exercise price are unique to Astria Therapeutics and Mr. Kishbauch's role, the mechanism itself is consistent with global benchmarks for incentivizing board members.
• Without specific comparable companies' director compensation details, a direct quantitative comparison is not feasible from this document alone.

Related Party Transactions

• The grant of 26,550 stock options to Director Michael D. Kishbauch constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors. This is a standard form of compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The stock options granted to Director Michael D. Kishbauch are scheduled to vest on June 11, 2026.

Key Dates

Keywords

Astria Therapeutics, ATXS, Stock Option, Insider Transaction, Director Compensation, Form 4, Beneficial Ownership, Equity Compensation